树脂钇90微球在肝外科治疗肝细胞癌的应用  

Application of resin yttrium 90 microspheres in liver surgery for treatment of hepatocellular carcinoma

作　　者：刘允怡[1] Wan Yee Lau(The Chinese Universty of Hong Kong Medical School Prince of Wales Hospital,Shatin,New Teritories,Hong Kong Special Adninistrative Region.P.R.China)

机构地区：[1]香港中文大学医学院,韦尔斯亲王医院,中国香港特别行政区新界沙田

出　　处：《中国普外基础与临床杂志》2022年第9期1124-1128,共5页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：钇90微球治疗原发性肝细胞癌(以下简称肝癌),有6个重要的发展里程碑,即从①肝癌不同治疗概念和②内放射治疗概念的建立,到③基础和临床研究到临床应用,找出④国际认可的姑息性治疗的不同适应证,发展到⑤从姑息性治疗到行根治性肝切除和肝移植,再发展到⑥使用非手术方法作为根治性治疗手段。这一发展路程十分长远,还会不断地发展下去。我国是肝癌高发国家,笔者坚信树脂钇90微球能获批准在我国作为治疗肝癌的手段,定会使很多肝癌患者获益。There are six important developmental milestones for yttrium 90 microspheres in treatment of hepatocellular carcinoma(HCC). These milestones are:① development of concepts in treatment of HCC;② development of concepts in internal radiation therapy;③ from basic, translational and clinical researches to clinical application;④ internationally recognized indications for palliative treat ment of HCC;⑤ from palliative to curative treatment of HCC after tumor downstaging with yttrium 90 microspheres using liver resection or liver transplantation;⑥ non-surgical treatments using yttrium 90 microsphere as curative treatments. The developmental stages of yttrium 90 microsphere in treatment of HCC have undergone a very prolonged period and these stages will continue to evolve. As HCC is prevalent in China, permission of the State Food and Drug Administration to allow yttrium 90 microsphere to be clinically used on HCC patients in China will benefit a lot of patients who were not treatable by other means.

关 键 词：钇90微球 肝细胞癌 选择性内放射治疗 经动脉放射栓塞 

分 类 号：R735.7[医药卫生—肿瘤]